CL2017003144A1 - Péptidos lipidados resistentes a proteasas - Google Patents

Péptidos lipidados resistentes a proteasas

Info

Publication number
CL2017003144A1
CL2017003144A1 CL2017003144A CL2017003144A CL2017003144A1 CL 2017003144 A1 CL2017003144 A1 CL 2017003144A1 CL 2017003144 A CL2017003144 A CL 2017003144A CL 2017003144 A CL2017003144 A CL 2017003144A CL 2017003144 A1 CL2017003144 A1 CL 2017003144A1
Authority
CL
Chile
Prior art keywords
peptides
amino acids
protein resistant
lipid peptides
resistant lipid
Prior art date
Application number
CL2017003144A
Other languages
English (en)
Inventor
Jefferson D Revell
Maria A Bednarek
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CL2017003144A1 publication Critical patent/CL2017003144A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA PÉPTIDOS RESISTENTES A PROTEASAS, MÉTODOS DE PREPARACIÓN DE TALES PÉPTIDOS, ASÍ COMO COMPOSICIONES QUE COMPRENDEN PÉPTIDOS RESISTENTES A PROTEASAS Y MÉTODOS DE TRATAMIENTO QUE UTILIZAN TALES PÉPTIDOS. UNA COMBINACIÓN DE LIPIDACIÓN DE DETERMINADOS RESIDUOS DE AMINOÁCIDOS Y SUSTITUCIÓN DE AMINOÁCIDOS FUNCIONALIZADOS CON ALFAMETILO EN LUGAR DE AMINOÁCIDOS NATURALES PARA PRODUCIR PÉPTIDOS RESISTENTES A PROTEASAS.</p>
CL2017003144A 2015-06-10 2017-12-07 Péptidos lipidados resistentes a proteasas CL2017003144A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US201662343390P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
CL2017003144A1 true CL2017003144A1 (es) 2018-04-13

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003144A CL2017003144A1 (es) 2015-06-10 2017-12-07 Péptidos lipidados resistentes a proteasas

Country Status (25)

Country Link
US (3) US10414811B2 (es)
EP (2) EP3307769B1 (es)
JP (1) JP6811190B2 (es)
KR (1) KR20180016441A (es)
CN (1) CN108271373B (es)
AU (2) AU2016277449B2 (es)
CA (1) CA2988841C (es)
CL (1) CL2017003144A1 (es)
CO (1) CO2017012675A2 (es)
CR (1) CR20170559A (es)
DO (1) DOP2017000287A (es)
EA (1) EA036415B1 (es)
ES (1) ES2849950T3 (es)
IL (1) IL255978B (es)
MX (1) MX389407B (es)
MY (1) MY185816A (es)
NI (1) NI201700156A (es)
NZ (1) NZ738909A (es)
PE (1) PE20180659A1 (es)
PH (1) PH12017502259A1 (es)
SG (1) SG10201911837SA (es)
SV (1) SV2017005585A (es)
TN (1) TN2017000519A1 (es)
TW (1) TWI726889B (es)
WO (1) WO2016198544A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190017017A (ko) * 2016-06-09 2019-02-19 메디뮨 리미티드 프로테아제-내성 모노-지질화된 펩타이드
EP3703817A4 (en) * 2017-10-31 2021-08-18 Medimmune Limited ORAL ADMINISTRATION OF GLP-1 PEPTIDE ANALOGA
ES2980707T3 (es) 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
EP4281464A4 (en) 2021-01-20 2025-01-01 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
EP1940438A4 (en) * 2005-09-08 2009-10-21 Tufts College STABILIZED GLP-1 ANALOGUES
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
HRP20110368T1 (hr) 2007-06-21 2011-06-30 Technische Universitt Mnchen Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
CA2707448C (en) 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
CN102307897B (zh) * 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
CA2902352A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
MX2016007407A (es) 2013-12-13 2016-12-12 Medimmune Ltd Peptidos resistentes a proteasa.

Also Published As

Publication number Publication date
EA201792640A1 (ru) 2018-06-29
EP3865504A1 (en) 2021-08-18
KR20180016441A (ko) 2018-02-14
IL255978B (en) 2021-04-29
US20210221866A1 (en) 2021-07-22
MX2017015482A (es) 2018-02-09
CN108271373A (zh) 2018-07-10
MX389407B (es) 2025-03-20
EA036415B1 (ru) 2020-11-09
WO2016198544A1 (en) 2016-12-15
EP3307769B1 (en) 2020-12-02
CO2017012675A2 (es) 2018-02-28
AU2016277449A1 (en) 2018-02-01
AU2019229424A1 (en) 2019-10-03
TN2017000519A1 (en) 2019-04-12
PE20180659A1 (es) 2018-04-17
CR20170559A (es) 2018-05-11
AU2016277449B2 (en) 2019-06-20
MY185816A (en) 2021-06-10
US20180162920A1 (en) 2018-06-14
IL255978A (en) 2018-01-31
US10414811B2 (en) 2019-09-17
SG10201911837SA (en) 2020-01-30
JP2018518485A (ja) 2018-07-12
NZ738909A (en) 2019-08-30
SV2017005585A (es) 2018-05-22
TWI726889B (zh) 2021-05-11
TW201710287A (zh) 2017-03-16
JP6811190B2 (ja) 2021-01-13
CA2988841C (en) 2023-06-06
EP3307769A1 (en) 2018-04-18
PH12017502259A1 (en) 2018-06-25
NI201700156A (es) 2018-10-18
DOP2017000287A (es) 2018-04-15
ES2849950T3 (es) 2021-08-24
US20200079833A1 (en) 2020-03-12
CN108271373B (zh) 2021-12-28
CA2988841A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
MX2019011764A (es) Composiciones limpiadoras y usos de las mismas.
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
CY1121560T1 (el) Ανοσογονικη συνθεση
CL2017002066A1 (es) Proteasas de cisteína
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2016013034A (es) Composicion detergente.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX2017001432A (es) Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PL3226854T3 (pl) Kompozycja na bazie aminokwasów do odbudowy fibroelastyny w tkance łącznej skóry
MX2017008454A (es) Peptidos y su uso en el tratamiento de la piel.
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
BR112016013157A2 (pt) peptídeos resistentes à protease
CL2020000733A1 (es) Proteína de fusión que comprende una porción de fgf-18.
MX390924B (es) Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa.
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
PH12017500742A1 (en) Statherin peptides
BR112016019389A2 (pt) vacina, e, peptídeo
MX2018003445A (es) Expresion de proteinas que contienen fc.